Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors

mBio

Volumn 5, Issue 3, 2014, Pages

  Rappocciolo, Giovanna ^a   Jais, Mariel ^a   Piazza, Paolo ^a   Reinhart, Todd A ^a   Berendam, Stella J ^a   Garcia Exposito, Laura ^a   Gupta, Phalguni ^a,b   Rinaldo, Charles R ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CHEMOKINE RECEPTOR CCR5; CHOLESTEROL; HLA B57 ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; CASE CONTROL STUDY; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MUTATION; PHYSIOLOGY; VIROLOGY;

B-LYMPHOCYTES; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; DENDRITIC CELLS; DISEASE PROGRESSION; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RECEPTORS, CCR5; VIRAL LOAD;

EID: 84903978033     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01031-13     Document Type: Article

References (38)

1. Walker BD, Yu XG. 2013. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13: 487-498. http://dx. doi. org/10. 1038/nri3478.
2. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, Hale B, Crum-Cianflone N, Delmar J, Barthel V, Quinnan G, Agan BK, Dolan MJ, Infectious Disease Clinical Research Program (IDCRP)HIV Working Group. 2009. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV Natural History Study. J. Infect. Dis. 200: 1714-1723. http://dx. doi. org/10. 1086/646609.
3. Thèze J, Chakrabarti LA, Vingert B, Porichis F, Kaufmann DE. 2011. HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin. Immunol. 141: 15-30. http://dx. doi. org/10. 1016/j. clim. 2011. 07. 007.
4. Geijtenbeek TB, van Kooyk Y. 2003. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276: 31-54. http://dx. doi. org/10. 1007/978-3-662-06508-2+2.
5. Fairman P, Angel JB. 2012. The effect of human immunodeficiency virus-1 on monocyte-derived dendritic cell maturation and function. Clin. Exp. Immunol. 170: 101-113. http://dx. doi. org/10. 1111/j. 1365-2249. 2012. 04628. x.
6. Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, Rowe DT, Jais M, Gupta P, Rinaldo CR. 2006. DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog. 2: e70. http://dx. doi. org/10. 1371/journal. ppat. 0020070.
7. Rinaldo CR. 2013. HIV-1 trans infection of CD4+ T cells by professional antigen presenting cells. Scientifica (Cairo) 2013: 164203. http://dx. doi. org/10. 1155/2013/164203.
8. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98. http://dx. doi. org/10. 1038/nature10347.
9. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. 2010. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 6: e1000981. http://dx. doi. org/10. 1371/journal. ppat. 1000981.
10. Hanley TM, Viglianti GA. 2011. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J. Virol. 85: 10834-10850. http://dx. doi. org/10. 1128/JVI. 00789-11.
11. Morrow MP, Grant A, Mujawar Z, Dubrovsky L, Pushkarsky T, Kiselyeva Y, Jennelle L, Mukhamedova N, Remaley AT, Kashanchi F, Sviridov D, Bukrinsky M. 2010. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol. Pharmacol. 78: 215-225. http://dx. doi. org/10. 1124/mol. 110. 065029.
12. Cui HL, Grant A, Mukhamedova N, Pushkarsky T, Jennelle L, Dubrovsky L, Gaus K, Fitzgerald ML, Sviridov D, Bukrinsky M. 2012. HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. J. Lipid Res. 53: 696-708. http://dx. doi. org/10. 1194/jlr. M023119.
13. Detels R, Jacobson L, Margolick J, Martinez-Maza O, Muñoz A, Phair J, Rinaldo C, Wolinsky S. 2012. The multicenter AIDS Cohort Study, 1983 to. Public Health 126: 196-198. http://dx. doi. org/10. 1016/j. puhe. 2011. 11. 013.
14. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97: 2709-2714. http://dx. doi. org/10. 1073/pnas. 050567397.
15. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2: 1240-1243. http://dx. doi. org/10. 1038/nm1196-1240.
16. Padilla J, Leung E, Phipps RP. 2002. Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. Clin. Immunol. 103: 22-33. http://dx. doi. org/10. 1006/clim. 2001. 5181.
17. Heine G, Dahten A, Hilt K, Ernst D, Milovanovic M, Hartmann B, Worm M. 2009. Liver X receptors control IgE expression in B cells. J. Immunol. 182: 5276-5282. http://dx. doi. org/10. 4049/jimmunol. 0801804.
18. del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña JM, Rodríguez-Zapata M, Alvarez-Mon M, Martínez-A C, Mañes S. 2004. Statins inhibit HIV-1 infection by downregulating Rho activity. J. Exp. Med. 200: 541-547. http://dx. doi. org/10. 1084/jem. 20040061.
19. Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, Delfraissy JF, Pancino G, Lambotte O. 2007. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 21: 1043-1045. http://dx. doi. org/10. 1097/QAD. 0b013e3280d5a7ac.
20. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN. 2011. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc. Natl. Acad. Sci. U. S. A. 108: E689-E698. http://dx. doi. org/10. 1073/pnas. 1108866108.
21. Liao Z, Graham DR, Hildreth JE. 2003. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res. Hum. Retrovir. 19: 675-687. http://dx. doi. org/10. 1089/088922203322280900.
22. Brezski RJ, Monroe JG. 2007. B cell antigen receptor-induced Rac1 activation and Rac1-dependent spreading are impaired in transitional immature B cells due to levels of membrane cholesterol. J. Immunol. 179: 4464-4472.
23. Szatmari I, Nagy L. 2008. Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function. EMBO J. 27: 2353-2362. http://dx. doi. org/10. 1038/emboj. 2008. 160.
24. Yuseff MI, Lankar D, Lennon-Duménil AM. 2009. Dynamics of membrane trafficking downstream of B and T cell receptor engagement: impact on immune synapses. Traffic 10: 629-636. http://dx. doi. org/10. 1111/j. 1600-0854. 2009. 00913. x.
25. Wang SH, Yuan SG, Peng DQ, Zhao SP. 2010. High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising anti-atherogenic strategy. Clin. Exp. Immunol. 160: 137-142. http://dx. doi. org/10. 1111/j. 1365-2249. 2009. 04068. x.
26. de Mello Coelho V, Nguyen D, Giri B, Bunbury A, Schaffer E, Taub DD. 2013. Quantitative differences in lipid raft components between murine CD4+ and CD8+ T cells. BMC Immunol. 5: 2. http://dx. doi. org/10. 1186/1471-2172-5-2.
27. Permanyer M, Pauls E, Badia R, Esté JA, Ballana E. 2013. The cortical actin determines different susceptibility of naive and memory CD4+ T cells to HIV-1 cell-to-cell transmission and infection. PLoS One 8: e79221. http://dx. doi. org/10. 1371/journal. pone. 0079221.
28. Wang W, Guo J, Yu D, Vorster PJ, Chen W, Wu Y. 2012. A dichotomy in cortical actin and chemotactic actin activity between human memory and naive T cells contributes to their differential susceptibility to HIV-1 infection. J. Biol. Chem. 287: 35455-35469. http://dx. doi. org/10. 1074/jbc. M112. 362400.
29. Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, Stephany DA, Cooper JN, Marsh JW, Wu Y. 2008. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134: 782-792. http://dx. doi. org/10. 1016/j. cell. 2008. 06. 036.
30. Gilbert C, Bergeron M, Méthot S, Giguère JF, Tremblay MJ. 2005. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol. 18: 474-489. http://dx. doi. org/10. 1089/vim. 2005. 18. 474.
31. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, Clotet B, Esté JA. 2005. Evaluation of the anti-HIV activity of statins. AIDS 19: 1697-1700. doi: 10. 1097/01. aids. 0000183517. 60384. db.
32. Montoya CJ, Jaimes F, Higuita EA, Convers-Páez S, Estrada S, Gutierrez F, Amariles P, Giraldo N, Peñaloza C, Rugeles MT. 2009. Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 10: 41. http://dx. doi. org/10. 1186/1745-6215-10-41.
33. Moore RD, Bartlett JG, Gallant JE. 2011. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 6: e21843. http://dx. doi. org/10. 1371/journal. pone. 0021843.
34. Montoya CJ, Higuita EA, Estrada S, Gutierrez FJ, Amariles P, Giraldo NA, Jimenez MM, Velasquez CP, Leon AL, Rugeles MT, Jaimes FA. 2012. Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305). J. Infect. 65: 549-558. doi: 10. 1016/j. jinf. 2012. 10. 016.
35. Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP. 2007. Statins disrupt CCR5 and RANTES expression levels in CD4(_) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One 2: e470. http://dx. doi. org/10. 1371/journal. pone. 0000470.
36. Rappocciolo G, Jenkins FJ, Hensler HR, Piazza P, Jais M, Borowski L, Watkins SC, Rinaldo CR, Jr. 2006. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J. Immunol. 176: 1741-1749.
37. Balachandran R, Thampatty P, Enrico A, Rinaldo C, Gupta P. 1991. Human immunodeficiency virus isolates from asymptomatic homosexual men and from AIDS patients have distinct biologic and genetic properties. Virology 180: 229-238. doi: 10. 1016/0042-6822(91)90027-9.
38. Sanghavi SK, Reinhart TA. 2005. Increased expression of TLR3 in lymph nodes during simian immunodeficiency virus infection: implications for inflammation and immunodeficiency. J. Immunol. 175: 5314-5323.